D. Huntjens

发表

A comparison of RSV and influenza in vitro kinetic parameters reveals differences in infecting time

D. Roymans, H. Dobrovolny, G. González-Parra, 2018, PloS one.

Prediction of human CNS pharmacokinetics using a physiologically‐based pharmacokinetic modeling approach

M. Danhof, M. Beukers, J. Proost, 2018, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats

M. Danhof, S. Summerfield, O. Della Pasqua, 2008 .

Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats

M. Danhof, S. Summerfield, D. Huntjens, 2008 .

Pharmacokinetic-pharmacodynamic correlations and biomarkers in the development of COX-2 inhibitors.

M. Danhof, O. Della Pasqua, D. Huntjens, 2005, Rheumatology.

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

L. Kwanten, J. McLellan, P. Rigaux, 2017, Nature Communications.

Differences in the in vitro and in vivo concentration-effect relationship of selective and non-selective COX inhibitors : role of translational pharmacology in pain research

M. Danhof, D. Huntjens, D. Spalding, 2008 .

A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations

M. Danhof, J. Proost, W. Couet, 2016, Pharmaceutical Research.

Respiratory syncytial virus-A dynamics and the effects of lumicitabine, a nucleoside viral replication inhibitor, in experimentally infected humans

Qingling Zhang, D. Huntjens, J. Symons, 2018, The Journal of antimicrobial chemotherapy.

Antiviral Activity of Oral JNJ-53718678 in Healthy Adult Volunteers Challenged With Respiratory Syncytial Virus: A Placebo-Controlled Study

D. Roymans, Young-In Kim, D. Huntjens, 2018, The Journal of infectious diseases.

Differences in the sensitivity of behavioural measures of pain to the selectivity of cyclo‐oxygenase inhibitors

M. Danhof, D. Huntjens, D. Spalding, 2009, European journal of pain.

Model-based prediction of the effect of COX inhibitors and optimal dosing in patients with systemic lupus erythematosus

M. Danhof, E. Donadi, D. Huntjens, 2008 .

1958. Antiviral Effects, Pharmacokinetics (PK), and Safety of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678 (JNJ-8678), in RSV-infected Infants With Bronchiolitis, in the Phase 1b Study 53718678RSV1005

E. Baraldi, F. Martinón-Torres, D. Huntjens, 2018, Open Forum Infectious Diseases.

University of Groningen Modeling of prolactin response following dopamine Dreceptor antagonists in rats

M. Danhof, J. Proost, A. Taneja, 2018 .

Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients

R. Bursi, D. Huntjens, C. Piana, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

Integrating Duodenal Sampling in a Human Mass Balance Study to Quantify the Elimination Pathways of JNJ-53718678, a Respiratory Syncytial Virus Fusion Protein Inhibitor

D. Huntjens, B. Remmerie, M. De Meulder, 2019, Advances in Therapy.

Pharmacokinetics, Safety, and Antiviral Effects of Multiple Doses of the Respiratory Syncytial Virus (RSV) Fusion Protein Inhibitor, JNJ-53718678, in Infants Hospitalized With RSV Infection: A Randomized Phase 1b Study

E. Baraldi, F. Martinón-Torres, D. Huntjens, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

PKPD correlations and biomarkers in the development of COX-2 inhibitors

M. Danhof, D. Huntjens, 2008 .

A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.

M. Danhof, J. Proost, A. Taneja, 2016, European journal of pharmacology.

Population Pharmacokinetic Modeling of Tapentadol Extended Release (ER) in Healthy Subjects and Patients with Moderate or Severe Chronic Pain

D. Huntjens, A. Vermeulen, P. Nandy, 2016, Clinical Drug Investigation.

Evaluation of the Population Pharmacokinetic Properties of Lidocaine and its Metabolites After Long-Term Multiple Applications of a Lidocaine Plaster in Post-Herpetic Neuralgia Patients

R. Bursi, D. Huntjens, C. Piana, 2017, European Journal of Drug Metabolism and Pharmacokinetics.

Predicting Drug Concentration‐Time Profiles in Multiple CNS Compartments Using a Comprehensive Physiologically‐Based Pharmacokinetic Model

M. Danhof, M. Beukers, J. Proost, 2017, CPT: pharmacometrics & systems pharmacology.

A human challenge model for respiratory syncytial virus kinetics, the pharmacological effect of a novel fusion inhibitor, and the modelling of symptoms scores

D. Huntjens, J. Devincenzo, B. Green, 2017, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

J. McLellan, P. Rigaux, D. Roymans, 2017, Nature Communications.

Population Pharmacokinetic Modeling of JNJ-53718678, a Novel Fusion Inhibitor for the Treatment of Respiratory Syncytial Virus: Results from a Phase I, Double-Blind, Randomized, Placebo-Controlled First-in-Human Study in Healthy Adult Subjects

D. Huntjens, A. Brochot, S. Ouwerkerk-Mahadevan, 2017, Clinical Pharmacokinetics.

Impact of chronic inflammation on the pharmacokinetic–pharmacodynamic relationship of naproxen

M. Danhof, D. Huntjens, D. Spalding, 2010, European journal of pain.

In vitro and in silico analysis of the effects of D 2 receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations

M. Danhof, P. H. van der Graaf, S. Gul, 2018, British journal of pharmacology.

Correlation between in vitro and in vivo concentration–effect relationships of naproxen in rats and healthy volunteers

M. Danhof, O. Della Pasqua, D. Huntjens, 2006, British journal of pharmacology.

A Generic Multi-Compartmental CNS Distribution Model Structure for 9 Drugs Allows Prediction of Human Brain Target Site Concentrations

M. Danhof, J. Proost, W. Couet, 2016, Pharmaceutical Research.

Unravelling the relationship between exposure , biomarker and analgesic response to COX inhibitors in chronic inflammatory pain

M. Danhof, D. Huntjens, O. Pasqua, 2008 .

Population pharmacokinetic modelling of the enterohepatic recirculation of diclofenac and rofecoxib in rats

D. Huntjens, A. Strougo, O. Pasqua, 2008, British journal of pharmacology.

CROCuS, a Phase II Study Evaluating the Antiviral Activity, Clinical Outcomes, and Safety of Rilematovir in Children Aged ≥ 28 Days and ≤ 3 Years with Acute Respiratory Tract Infection Due to Respiratory Syncytial Virus

M. Gamil, D. Huntjens, T. Toh, 2024, Paediatric drugs.